Lakefront Biotherapeutics (GLPGF) Revenue Growth (1y) (2015 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Revenue Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 9.53% |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | 10.18% |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 12.45% |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 16.73% |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | 59.71% |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | 2.11% |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 66.86% |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | 3.42% |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -80.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -80.95% |
| Mar 31, 2026 | -90.38% |
| Dec 31, 2025 | 2,516.76% |
| Sep 30, 2025 | -53.51% |
| Jun 30, 2025 | 373.27% |
| Mar 31, 2025 | 16.28% |
| Dec 31, 2024 | -93.15% |
| Sep 30, 2024 | 168.52% |
| Jun 30, 2024 | -141.40% |
| Mar 31, 2024 | 7.88% |
| Dec 31, 2023 | 439.52% |
| Sep 30, 2023 | -51.49% |
| Jun 30, 2023 | -55.50% |
| Mar 31, 2023 | -58.92% |
| Dec 31, 2022 | -80.38% |
| Sep 30, 2022 | -63.38% |
| Jun 30, 2022 | -12.74% |
| Mar 31, 2022 | 11.39% |
| Dec 31, 2021 | -115.11% |
| Sep 30, 2021 | -0.29% |